Highlights

A lot of Avastin patients are switched in my practice to Eylea or now Vabysmo, and I’m trying to extend them […] I’m looking at Vabysmo more frequently to switch after initial Avastin usually.

The sub-responders or non-responders are not always well defined, but generally I think at least 50–60% of patients don’t have a completely dry retina, and don’t improve vision. So, I think that most patients are subresponders, it’s just that we sort of keep them where they are. It’s likely that probably 50–60% of my patients get switched to a commercial drug after starting with Avastin, but a significant proportion can stay on Avastin with decent results.

The dogma of durability has been most advanced by the Port Delivery System, but it’s a surgery. There is a fear of a new surgery for many folks who haven’t participated in the clinical trials, but yet it has the best durability.

But in 10 years, I’m hopeful that either the Port Delivery System gets safer, and better, and people get more comfort with it, or gene therapy comes along and seems to do what it would intend to do well, but we don’t know that, and safely.